Success Metrics

Clinical Success Rate
81.8%

Based on 9 completed trials

Completion Rate
82%(9/11)
Active Trials
1(7%)
Results Posted
89%(8 trials)
Terminated
2(13%)

Phase Distribution

Ph early_phase_1
1
7%
Ph phase_1
2
13%
Ph phase_3
4
27%
Ph phase_2
4
27%
Ph phase_4
3
20%

Phase Distribution

3

Early Stage

4

Mid Stage

7

Late Stage

Phase Distribution14 total trials
Early Phase 1First-in-human
1(7.1%)
Phase 1Safety & dosage
2(14.3%)
Phase 2Efficacy & side effects
4(28.6%)
Phase 3Large-scale testing
4(28.6%)
Phase 4Post-market surveillance
3(21.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.8%

9 of 11 finished

Non-Completion Rate

18.2%

2 ended early

Currently Active

1

trials recruiting

Total Trials

15

all time

Status Distribution
Active(1)
Completed(9)
Terminated(2)
Other(3)

Detailed Status

Completed9
unknown3
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
1
Success Rate
81.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (7.1%)
Phase 12 (14.3%)
Phase 24 (28.6%)
Phase 34 (28.6%)
Phase 43 (21.4%)

Trials by Status

active_not_recruiting17%
terminated213%
completed960%
unknown320%

Recent Activity

1 active trials
Showing 5 of 15
completedphase_3

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

NCT03621670
terminatedphase_2

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

NCT03376477
active_not_recruitingearly_phase_1

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

NCT03729778
terminatedphase_1

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

NCT02716805
unknownphase_4

Fourth Dose of mRNA COVID-19 Vaccine in Residents of LTCFs

NCT04978038
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT03621670Phase 3

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Completed
NCT03376477Phase 2

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

Terminated
NCT03729778Early Phase 1

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

Active Not Recruiting
NCT02716805Phase 1

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Terminated
NCT04978038Phase 4

Fourth Dose of mRNA COVID-19 Vaccine in Residents of LTCFs

Unknown
NCT02447718Phase 4

Vaccinating Children After Chemotherapy

Completed
NCT05145101

Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia

Unknown
NCT02927444Phase 3

Immunogenicity and Safety Study of NBP606 in Healthy Toddlers

Completed
NCT02201030Phase 3

Immunogenicity and Safety Study of NBP606 in Healthy Infants

Completed
NCT02096263Phase 3

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

Completed
NCT03467984Phase 2

A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants

Completed
NCT02422264Phase 4

Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

Completed
NCT01262872Phase 2

Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants

Completed
NCT01349569Phase 2

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

Completed
NCT03549208Phase 1

A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults

Unknown

All 15 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
15